Abstract JC virus (JCV) is a human polyomavirus that infects the central nervous system (CNS) of immunocompromised patients. JCV granule cell neuronopathy (JCV-GCN) is caused by infection of cerebellar granule cells, causing ataxia. A 77-year-old man with iatrogenic lymphopenia presented with severe ataxia and was diagnosed with JCV-GCN. His ataxia and cerebrospinal fluid (CSF) improved with intravenous immunoglobulin, high-dose intravenous methylprednisolone, mirtazapine, and mefloquine. Interleukin-7 (IL-7) therapy reconstituted his lymphocytes and reduced his CSF JCV load. One month after IL-7 therapy, he developed worsening ataxia and CSF inflammation, which raised suspicion for immune reconstitution inflammatory syndrome. Steroids were restarted and his ataxia stabilized.
Introduction
JC virus (JCV) is a human polyomavirus with high seroprevalence that causes a quiescent infection in the kidneys and urinary tract epithelium (Gheuens et al. 2013) . JCV invades the brain of immunocompromised people, causing lytic infections of oligodendroglial cells and demyelinating white matter lesions, which is known as progressive multifocal leukoencephalopathy (PML) (Brew et al. 2010) .
Rarely, JCValso infects neurons and glia in the gray matter. JCV granule cell neuronopathy (JCV-GCN) occurs when cerebellar granule cells are infected, causing subacute, progressive cerebellar ataxia. Mutations in the VP1 capsid protein of JCV confer the ability to infect granule cells (Dang and Koralnik 2006; Dang et al. 2012) . JCV-GCN has been documented in immunocompromised patients with human immunodeficiency virus (HIV), CD40 ligand deficiency, sarcoidosis, and immunosuppression after natalizumab or rituximab treatment (Hecht et al. 2007; Granot et al. 2009; Agnihotri et al. 2014; Dang et al. 2014) .
We report on JCV-GCN in a 77-year-old man with chronic lymphopenia, associated with prior chemotherapy. He presented with a progressive ataxia and an inflammatory cerebrospinal fluid (CSF) profile. We detail his clinical course including initial treatment with high-dose intravenous methylprednisolone (IVMP), intravenous immunoglobulin (IVIG), mirtazapine, and mefloquine, and later treatment with recombinant interleukin-7 (IL-7).
Patient and methods
A 77-year-old man with a history of mantle cell lymphoma, status-post chemotherapy with rituximab and bendamustine (2010), presented with 2 months of progressive truncal and appendicular ataxia, rendering him non-ambulatory (Fig. 1) . Prior to chemotherapy, his baseline absolute lymphocyte count (ALC) was 4000/μL, and immediately after chemotherapy, his ALC was 650/μL with a nadir of 300/μL. He was HIV negative, and he had a history of lung, bladder, and prostate cancers, all treated surgically. Additionally, he had chronic systolic heart failure and prior placement of a pacemaker/ automatic implantable cardioverter/defibrillator (PPM/ AICD) that was not magnetic resonance imaging (MRI) compatible.
His exam showed direction-changing nystagmus, dysmetric saccades, and truncal and appendicular ataxia, rendering him unable to stand without support. Intractable nausea and vomiting, worsened by movement, resulted in additional morbidity. Brain computed tomography (CT) with contrast showed cerebellar atrophy. His ALC was 600/μL and CSF showed RBC count 2382/μL, WBC count 52/μL (88 % lymphocytes), protein 56 mg/dL, and glucose 86 mg/dL. CSF cytology, flow cytometry, oligoclonal bands, and paraneoplastic antibodies were negative. A thorough screen for other etiologies of cerebellar ataxia was unrevealing (Fig. 2) . Whole-body 18 Fludeoxyglucose positron-emission tomography (PET)/CT scan showed cerebellar hypermetabolism and a right upper lobe pulmonary nodule. The nodule could not be accessed by minimally invasive biopsy procedures. Comparison to prior PET/ CT scans revealed that the nodule had not changed in 4 years, rendering malignancy unlikely.
Given the possibility of an inflammatory or paraneoplastic etiology, the patient was treated with high-dose IVMP (5 g total, over 5 days) and plasma exchange. After completion of IVMP, his direction-changing nystagmus and dysmetric saccades resolved. He was able to sit upright, he could manipulate a spoon without spilling food, and his nausea, vomiting, and anorexia improved. JCV-GCN was added to the differential diagnosis because of his lymphopenia. A qualitative PCR detected JCV in CSF. Plasma exchange was stopped after two sessions. An immune competence panel showed ALC 300/μL, CD4 count 74/μL (normal range 365-1294/μL), and CD8 count 157/μL (normal range 187-781/μL) with a CD4:CD8 ratio of 0.47. The trends for ALC, CD4, and CD8 counts are highlighted in Fig. 2 . Serum IgG was 289 mg/dL (normal r a n g e 7 0 0 -1 4 5 0 m g / d L ) . H e w a s t r e a t e d f o r hypogammaglobulinemia, in the context of an inflammatory CSF profile, with 50 g IVIG.
JCV DNA quantitative PCR (qPCR) was obtained from the first CSF sample, revealing 1328 copies/mL (Ryschkewitsch et al. 2013) . The trend of the JCV qPCR is highlighted in Fig. 2 . Repeat CSF studies after corticosteroid therapy showed RBC count 247/μL, WBC count 4/μL, glucose 86 mg/dL, protein 67 mg/dL, and JCV qPCR 2398 copies/mL. Treatment also included mirtazapine 15 mg daily and mefloquine 250 mg daily, for 3 days then once a week (Brickelmaier et al. 2009; Marzocchetti et al. 2009; Wenning et al. 2009; Clifford et al. 2010) .
Because of the patient's unanticipated, inflammatory CSF profile with detection of JCV, we sought to confirm the diagnosis of JCV-GCN. Biopsy of the left cerebellar hemisphere showed polyomavirus T-antigen-expressing cells and patchy areas of cell loss within the granule cell layer, without demyelinating lesions, findings consistent with JCV-GCN (Fig. 3) . The granule cell layer had marked T cell infiltration (Fig. 3) . JCV DNA was recovered from biopsy tissue, and direct DNA sequencing was performed on the VP1 gene region where JCV-GCN-associated mutations are found. Analysis of the associated amino acid sequence found a single change, lysine to arginine, at amino acid position 345 of the C terminus of the VP1 capsid protein. This mutation lies in the area where JCV-GCN mutations are commonly found, but this mutation leads to a conservative amino acid substitution rather than a deletion or change in reading frame, as previously reported JCV-GCN cases (Dang et al. 2012) . The mutation does not significantly alter the conformation of the VP1 capsid protein compared to wild-type JCV as modeled by the Expert Protein Analysis System (EXPASY) (data not shown). The genotype was consistent with JCV type 2 (Agostini et al. 1997) . His ataxia improved by the time of discharge. He could stand unsupported and walk with assistance. His ALC was 400/μL. Thirteen days after discharge, recombinant IL-7 therapy was administered as a 20 μg/kg subcutaneous injection once a week, for 3 weeks, in an attempt to promote immune recovery. The Washington University institutional review board approved the protocol and informed consent was obtained. There was additional clinical improvement (e.g., ambulating several steps independently). A lumbar puncture performed after completion of IL-7 therapy showed RBC count 0/μL, WBC count 49/μL, protein 71 mg/dL, glucose 55 mg/dL, and JCV qPCR 37 copies/mL.
One month after his last dose of IL-7, he presented with worsening ataxia. His ALC was 1500/μL and his CSF showed RBC count 0/μL, WBC count 49/μL, protein 78 mg/dL, and glucose 55 mg/dL. Given his clinical worsening despite an improved ALC, there was suspicion for immune reconstitution inflammatory syndrome (IRIS). He was restarted on IVMP, mirtazapine, and mefloquine. He was treated empirically because MRI could not be done and CT is insensitive for detection of IRIS. His symptoms stabilized but his ataxia (e.g., difficulty sitting upright without support) and chronic nausea and vomiting persist. His latest lumbar puncture, performed in the setting of weekly 1 g IVMP infusions, showed RBC count 0/μL, WBC count 21/μL, protein 52 mg/dL, glucose 65 mg/ dL, and JCV qPCR 65 copies/mL. His CD4 and CD8 counts were 433 and 570/μL, respectively.
Discussion
JCV-GCN should be considered in all lymphopenic patients with ataxia. CSF should be tested by JCV DNA PCR to establish the diagnosis. Genotyping is not necessary for diagnosis, but detection of known mutations in the C-terminus of the VP1 gene can be supportive. In this case, JCV present in the recovered tissue did not have the typical GCN mutations, which suggests that wild-type JCV also causes JCV-GCN. A growing body of literature shows that granule cells are frequently infected in patients with known PML lesions (Wijburg et al. 2015; Du Pasquier et al. 2003; Bustamante et al. 2009 ). There is ongoing debate whether this phenomenon is a consequence of a single, multifocal JCV infection or simultaneous infections from JCV variants with different tropisms. We would have liked to determine whether this patient had white matter lesions, but brain MRI could not be performed. Head CT with contrast did not show any suspicious lesions, but the sensitivity for detection of demyelinating lesions is poor compared to MRI. The cerebellar biopsy did not show demyelination.
Immunosuppressive therapies are a major risk factor for development of lymphopenia and resultant predisposition to JCV CNS infections. Our patient was previously treated with rituximab, a chimeric monoclonal antibody that depletes B cells. The relationship between rituximab and his JCV-GCN is unclear, for a couple of reasons. First, lymphopenia rarely lasts longer than 12 months after rituximab treatment (Lu et al. 2008) . Second, the patient's history of recurrent cancers suggests an underlying immune disorder that could have predisposed him to JCV infection of the CNS.
Currently, there is no approved therapy for JCV infection in patients without a reversible, acquired lymphopenia. IL-7 is a rational therapy because it promotes rapid maturation and mobilization of available lymphocyte stores. After IL-7 therapy, our patient's ALC, CD4, and CD8 counts normalized, and these improvements were inversely correlated with CSF JCV viral load. These results are consistent with other reports of IL-7 therapy (Alstadhaug et al. 2014; Gasnault et al. 2014) . Unfortunately, at the time of publication, the drop in JCV viral load did not translate into additional clinical benefit for our patient.
The inflammatory nature of the patient's JCV-GCN is unique. After completion of the first round of IVMP, the patient's inflammatory CSF profile and ataxia markedly improved. Classically, PML and JCV-GCN are not associated with inflammation. If viral infection were the cause of inflammation, one would expect that reduction of the viral load by IL-7 therapy would reduce the inflammation, but this was not evident. The inflammation may be a consequence of his strengthened immune system attacking a persistent low-level JCV infection or it may be a consequence of the IL-7 therapy itself. He continues to receive regular low-dose oral steroid therapy, which has stabilized his symptoms.
